Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen GAAP Effective Tax Rate: 14.2% in Q2 2026, up 5.5 pts from a year earlier.
Latest, Q2 2026
14.2%
Period ended Jun 30, 2026
Change on a year earlier
+5.5 pts
8.7% in Q2 2025
History
44 quarters
Since Q1 2015
Sources
36
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K & Form 8-K Reconciliations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen GAAP Effective Tax Rate (%), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-tax-rate-8k
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.